ArticleOsteoarthritis imaging2025
Deconstructing the "types" of osteoarthritis.
Article in Osteoarthritis imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Perspective: One and one make three - leveraging the synergy of imaging and biomechanics in osteoarthritis research and care.Osteoarthritis imaging · 2026Article
- Editorial: Special issue imaging and pain.Osteoarthritis imaging · 2026Article
- Recent Advances in Therapeutic Approaches for Knee Osteoarthritis: a Narrative Review.Biomolecules & therapeutics · 2026Review
- Focus on the NLRP3 inflammasome: its role in the pathogenesis and therapeutic potential of inflammation-driven osteoarthritis.Frontiers in immunology · 2026Review
- Macrophages: pivotal orchestrators and emerging therapeutic targets in osteoarthritis pathogenesis.Journal of translational medicine · 2025Review
- The 18th international workshop on osteoarthritis imaging. Structure and pain: Where are we today?Osteoarthritis imaging · 2025Review
- Unraveling the Scientific Landscape of Osteoarthritis: Dynamics of Publications over Five Decades.Bioengineering (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The community acknowledges the staggering prevalence and disabling nature of osteoarthritis, and the crucial need for therapeutic advancement. In our quest to define a clinically meaningful endpoint and identify biomarkers that can serve as short-term treatment responses and reliable predictors of long-term outcomes, we must also strive to target therapies more effectively. This perspective article not only aims to elucidate the nomenclature of osteoarthritis types but also proposes a path towards greater transparency that has the potential to inspire a new era of both research and clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.